Testing entrectinib in babies and toddlers with certain brain tumors
Original title: Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the drug is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a drug called entrectinib in very young children whose brain tumors have a certain gene change.
Who this trial is for. This trial is for children under 3 years old with a high grade glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary or another tumor of the brain or spinal cord. The tumor must have an NTRK 1/2/3 or ROS1 gene fusion. The trial tests how well a drug called entrectinib works as the first treatment.
Where it stands. There are no results yet. The trial is measuring how well entrectinib works in these children. That answer is not in yet.
What this means, and what it doesn't
What it could mean: Parents of a very young child with one of these gene changes could ask their care team about this trial. The care team can explain if it might be a fit.
What it doesn't mean: This does not mean the drug is proven to work. A trial is a test, not a treatment you know will help. Being in a trial does not promise any benefit. It is not a promise of a cure.
Source: ClinicalTrials.gov, November 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.